What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Radiation therapy
Ritsuko Komaki spends much of her time researching Radiation therapy, Lung cancer, Surgery, Internal medicine and Oncology.
Her research in Radiation therapy intersects with topics in Nuclear medicine, Carcinoma, Lung and Chemotherapy.
Her work investigates the relationship between Chemotherapy and topics such as Clinical trial that intersect with problems in Vinblastine.
Her research integrates issues of Cancer, Respiratory disease, Randomized controlled trial, Radiosurgery and Pneumonitis in her study of Lung cancer.
In her study, Hazard ratio is inextricably linked to Proportional hazards model, which falls within the broad field of Oncology.
Her Radiology research also works with subjects such as
- Esophagus and related Brachial plexus,
- Esophageal cancer that intertwine with fields like Adenocarcinoma.
Her most cited work include:
- Non–Small Cell Lung Cancer (1248 citations)
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study (1133 citations)
- Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide (1121 citations)
What are the main themes of her work throughout her whole career to date?
Ritsuko Komaki focuses on Radiation therapy, Internal medicine, Lung cancer, Oncology and Surgery.
Ritsuko Komaki interconnects Nuclear medicine, Cancer, Carcinoma and Chemotherapy in the investigation of issues within Radiation therapy.
Her research brings together the fields of Gastroenterology and Internal medicine.
She combines subjects such as Stage, Pneumonitis and Hazard ratio with her study of Lung cancer.
The Oncology study combines topics in areas such as Clinical trial, Phases of clinical research and Randomized controlled trial.
Her Radiology research incorporates themes from Esophagus and Lung.
She most often published in these fields:
- Radiation therapy (54.23%)
- Internal medicine (45.45%)
- Lung cancer (41.31%)
What were the highlights of her more recent work (between 2013-2021)?
- Internal medicine (45.45%)
- Radiation therapy (54.23%)
- Oncology (35.41%)
In recent papers she was focusing on the following fields of study:
Her primary scientific interests are in Internal medicine, Radiation therapy, Oncology, Lung cancer and Surgery.
Ritsuko Komaki works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Definitive chemoradiotherapy and Toxicity.
Her Radiation therapy research is multidisciplinary, incorporating perspectives in Stage, Clinical trial and Nuclear medicine.
The concepts of her Oncology study are interwoven with issues in Survival rate, Multivariate analysis and Chemotherapy.
Her study in Lung cancer is interdisciplinary in nature, drawing from both Cancer research, Carcinoma, Immunology and Hazard ratio.
Her work on Retrospective cohort study, Randomized controlled trial and Common Terminology Criteria for Adverse Events as part of general Surgery research is often related to SABR volatility model, thus linking different fields of science.
Between 2013 and 2021, her most popular works were:
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study (1133 citations)
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials (839 citations)
- Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology (746 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Radiation therapy
Ritsuko Komaki mainly investigates Radiation therapy, Internal medicine, Lung cancer, Oncology and Surgery.
Her Radiation therapy research is classified as research in Radiology.
In general Internal medicine study, her work on Esophageal cancer, Chemoradiotherapy and Carcinoma often relates to the realm of In patient, thereby connecting several areas of interest.
Her Lung cancer research is multidisciplinary, incorporating elements of Cancer, Cancer research, Survival rate, Immunology and Lung.
Her biological study spans a wide range of topics, including Carboplatin, Combined Modality Therapy, Pembrolizumab and Stage.
Ritsuko Komaki usually deals with Surgery and limits it to topics linked to Confidence interval and Primary tumor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
